Glaukos Corporation appears in FDA device records as the applicant for a single premarket approval, P170043, covering the iStent inject Trabecular Micro-Bypass System (Model G2-M-IS). The supplied collection holds two linked PMA records for this applicant: the original approval and one later supplement. Both are class 3 intraocular pressure lowering implants reviewed by the Ophthalmic advisory committee. The company also publishes instructions for use and product pages for the iStent inject W family on its own site. [1][2][3][4]
The original approval and its stated indication
FDA approved P170043 on June 21, 2018, with decision code APPR, for the iStent inject Trabecular Micro-Bypass System (Model G2-M-IS). The application was received December 21, 2017, and carries docket number 18M-2460. The approval statement describes the device as indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild to moderate primary open-angle glaucoma. The Summary of Safety and Effectiveness Data lists the same generic name, trade name, product code OGO and applicant address in San Clemente, California. [2][10]
The FDA database entry for P170043 notes that the device has supplements and that the device description or indication may have changed, so the labeling shown is the version at the time of approval. The same page lists supplements S007 through S023, including S023. [5]
A 2026 manufacturing supplement
Supplement P170043/S023 was received September 1, 2026, and decided October 1, 2026, under decision code OK30 as a 30-Day Notice. The supplement reason is recorded as a process change affecting manufacturer, sterilizer, packager or supplier. The applicant's statement describes four changes: an instruction for use change from printed to electronic format, an updated sustainable shipper box, a reduced incoming inspection sampling plan for the Trocar component, and an alternative location for final packaging, labeling and lot release operations on the existing manufacturing campus. The trade name in that record covers the iStent inject W Trabecular Micro-Bypass System and a variant with additional wording. [1]
Documented device components and labeling
Glaukos-published instructions for use describe the iStent inject W Trabecular Micro-Bypass System and, separately, the iStent inject W Trabecular Micro-Bypass System with Infinite Injector Technology, Model iS2. The iS2 labeling states that the system contains two intraocular stents manufactured from implant grade titanium (Ti6Al4V ELI) coated with stearalkonium heparin, preloaded in one injector. The company's product page states the same indication language used in the FDA approval record: use in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild to moderate primary open-angle glaucoma. [3][4][6][7]
The iS2 instructions for use report an effectiveness cohort of 380 eyes randomized to the iStent inject group implanted with two stents and 118 subjects randomized to the control group. The company's clinical data page states that Glaukos exceeds 3 million iStent devices implanted. Both statements are attributed to their publishers; neither is an FDA determination in the linked FDA records. [6][8]
What the filing record does and does not establish
The supplied collection contains two linked PMA records, with decision counts of one OK30 and one APPR; the smaller record sample shows the same two decisions. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. No recall records appear in the sample. The records identify Glaukos Corporation as applicant at 229 Avenida Fabricante, San Clemente, California; that filing address is not treated here as a headquarters designation. Ownership, parent entities, customers and commercial availability are not established by these sources. [1][2][5]
